Phase 2 trial: Tarlatamab for Neuroendocrine Prostate Cancer (NEPC)
/in Clinical Trial, Metastatic, Phase 2/by MaxPhase Ib/II Study of TYK-00540 Combined With Enzalutamide in mCRPC
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase Ib/II Clinical Trial of TY-302 and Abiraterone Acetate in mCRPC
/in Clinical Trial, Phase 1, Phase 2/by MaxPhase 1/2 Trial for DS-3939a: A Novel TA-MUC1–Directed ADC for Advanced Prostate Cancer and Beyond
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxSummary of the PC-BETS Substudy C: Darolutamide in Biomarker-Selected mCRPC
/in Clinical Trial, Metastatic, Phase 2/by MaxEarly Results of Gedatolisib and Darolutamide in mCRPC Treatment
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1/2 For a New PARP1 Inhibitor: EIK1004 (IMP1707) For mCRPC
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1/2 Trial: MT-4561 Targeting BRD4 in Metastatic Prostate Cancer and Neuroendocrine Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxNEPC
Phase 2 Trial: ZG006 a New Immunotherapy for Neuroendocrine Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 30/2026 July 26, 2026
- Biallelic Loss in DDR Genes and Its Clinical Impact July 25, 2026
- How DNA “Switches” in Prostate Cancer May Open New Treatment Paths July 25, 2026
- UPDATE: VIR-5500 Extended into mHSPC July 24, 2026